Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhiping Li

Showing results (521-530 of 540) with videos related to

Pageof 54
Sort By:
Signal Transduction and Targeted Therapy|November 24, 2024
Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trialKe Cheng, Xiaoying Li, Wanrui Lv, et al.
Journal of Multidisciplinary Healthcare|March 3, 2023
Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma PatientsYuhao Zeng, Sha Zhu, Zilin Wang, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Chunmei Bai, et al.
Oncotarget|November 16, 2017
Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growthTimothy G Pestell, Xuanmao Jiao, Mukesh Kumar, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 16, 2023
Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinibJianwei Zhang, Haibin Zhu, Lin Shen, et al.
The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.
Cancer Research|January 24, 2018
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell ExpansionXuanmao Jiao, Marco A Velasco-Velázquez, Min Wang, et al.
Gastroenterology|April 16, 2018
Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic HepatitisBrian P Lee, Neil Mehta, Laura Platt, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2024
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trialPanpan Zhang, Si Shi, Jianming Xu, et al.
Pageof 54

Showing results (521-530 of 540) with videos related to

Sort By:
Pageof 54
Signal Transduction and Targeted Therapy|November 24, 2024
Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trialKe Cheng, Xiaoying Li, Wanrui Lv, et al.
Journal of Multidisciplinary Healthcare|March 3, 2023
Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma PatientsYuhao Zeng, Sha Zhu, Zilin Wang, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Chunmei Bai, et al.
Oncotarget|November 16, 2017
Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growthTimothy G Pestell, Xuanmao Jiao, Mukesh Kumar, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 16, 2023
Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinibJianwei Zhang, Haibin Zhu, Lin Shen, et al.
The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.
Cancer Research|January 24, 2018
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell ExpansionXuanmao Jiao, Marco A Velasco-Velázquez, Min Wang, et al.
Gastroenterology|April 16, 2018
Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic HepatitisBrian P Lee, Neil Mehta, Laura Platt, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2024
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trialPanpan Zhang, Si Shi, Jianming Xu, et al.
Pageof 54